Stocks Overview

LAST PRICE
59.7000
TODAY'S CHANGE (%)
Trending Down-0.0400 (-0.0670%)

Bid / Lots
59.7000/ 15
Ask / Lots
59.7100/ 4
Open / Previous Close
59.7600 / 59.7400
Day Range
Low 59.4718
High 59.8300
52 Week Range
Low 3.6000
High 59.9500
Volume
874,594
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 59.74
Time	Volume	LBPH
09:32 ET	26445	59.78
09:33 ET	22982	59.81
09:35 ET	5364	59.79
09:37 ET	7686	59.76
09:39 ET	5526	59.76
09:42 ET	8951	59.775
09:44 ET	44117	59.75
09:46 ET	2904	59.74
09:48 ET	9067	59.76
09:50 ET	32722	59.7399
09:51 ET	27924	59.73
09:53 ET	24185	59.725
09:55 ET	23219	59.725
09:57 ET	1826	59.72
10:00 ET	2713	59.73
10:02 ET	9117	59.73
10:04 ET	43833	59.72
10:06 ET	593	59.72
10:08 ET	3203	59.72
10:09 ET	4264	59.72
10:11 ET	48055	59.51
10:13 ET	24615	59.57
10:15 ET	7380	59.58
10:18 ET	15848	59.63
10:20 ET	12964	59.67
10:22 ET	2800	59.655
10:24 ET	6782	59.65
10:26 ET	3974	59.635
10:27 ET	1649	59.6
10:29 ET	4375	59.67
10:31 ET	28819	59.69
10:33 ET	1211	59.69
10:36 ET	4911	59.71
10:38 ET	13300	59.7
10:40 ET	2259	59.72
10:42 ET	699	59.7
10:44 ET	4772	59.71
10:45 ET	3730	59.72
10:47 ET	1272	59.7121
10:49 ET	300	59.72
10:51 ET	5050	59.715
10:54 ET	9361	59.74
10:56 ET	600	59.73
10:58 ET	400	59.75
11:00 ET	4191	59.75
11:02 ET	300	59.745
11:03 ET	1200	59.74
11:05 ET	1978	59.73
11:07 ET	1229	59.72
11:09 ET	1516	59.73
11:12 ET	2973	59.71
11:14 ET	1703	59.72
11:16 ET	3007	59.71
11:18 ET	3679	59.7
11:20 ET	4079	59.69
11:21 ET	5207	59.71
11:23 ET	1200	59.71
11:25 ET	401	59.71
11:27 ET	1344	59.705
11:30 ET	788	59.715
11:32 ET	400	59.715
11:34 ET	1652	59.715
11:36 ET	3329	59.73
11:38 ET	800	59.73
11:39 ET	500	59.73
11:41 ET	2060	59.72
11:43 ET	1481	59.715
11:45 ET	1849	59.7
11:48 ET	2565	59.71
11:50 ET	900	59.715
11:52 ET	1253	59.7
11:54 ET	2789	59.705
11:56 ET	500	59.705
11:57 ET	100	59.705
11:59 ET	1400	59.71
12:01 ET	200	59.705
12:03 ET	1487	59.71
12:06 ET	400	59.71
12:08 ET	600	59.715
12:10 ET	52837	59.74
12:12 ET	2887	59.745
12:14 ET	100	59.75
12:15 ET	500	59.7475
12:17 ET	738	59.75
12:19 ET	600	59.745
12:21 ET	100	59.745
12:24 ET	100	59.745
12:26 ET	1779	59.745
12:28 ET	1191	59.745
12:30 ET	900	59.74
12:32 ET	1000	59.735
12:33 ET	2224	59.74
12:35 ET	3899	59.74
12:37 ET	3921	59.735
12:39 ET	300	59.735
12:42 ET	1261	59.73
12:44 ET	200	59.73
12:46 ET	600	59.73
12:48 ET	2272	59.725
12:50 ET	2864	59.71
12:51 ET	3606	59.72
12:53 ET	2390	59.73
12:55 ET	500	59.73
12:57 ET	501	59.73
01:00 ET	1315	59.74
01:02 ET	4458	59.72
01:06 ET	300	59.7275
01:08 ET	2146	59.73
01:09 ET	37817	59.71
01:11 ET	1053	59.71
01:13 ET	4500	59.715
01:15 ET	900	59.71
01:18 ET	5191	59.71
01:20 ET	900	59.71
01:22 ET	300	59.71
01:24 ET	200	59.71
01:26 ET	900	59.72
01:27 ET	551	59.715
01:29 ET	1295	59.72
01:31 ET	2650	59.74
01:33 ET	300	59.74
01:36 ET	1758	59.73
01:38 ET	705	59.73
01:40 ET	100	59.74
01:42 ET	2736	59.735
01:45 ET	1638	59.74
01:47 ET	500	59.735
01:49 ET	2993	59.75
01:54 ET	4061	59.74
01:56 ET	400	59.74
01:58 ET	4502	59.72
02:00 ET	600	59.72
02:02 ET	169	59.72
02:03 ET	200	59.725
02:05 ET	600	59.725
02:07 ET	100	59.725
02:09 ET	200	59.725
02:12 ET	500	59.725
02:14 ET	100	59.725
02:16 ET	695	59.725
02:20 ET	400	59.725
02:21 ET	2101	59.72
02:23 ET	3095	59.715
02:25 ET	1809	59.715
02:27 ET	100	59.715
02:30 ET	500	59.715
02:32 ET	300	59.715
02:34 ET	550	59.72
02:36 ET	500	59.715
02:38 ET	300	59.715
02:39 ET	3062	59.71
02:41 ET	3049	59.7
02:43 ET	996	59.7

Data delayed at least 15 minutes.

Nov 12, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by Dow Jones
  1:20PM ET on Tuesday Nov 12, 2024 by Dow Jones
- Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs), from 8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
- Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 1, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of Shareholders, from 12:06PM ET on Friday Nov 01, 2024 by Dow Jones
  12:06PM ET on Friday Nov 01, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesLBPH Longboard Pharmaceuticals Inc	2.3B	-26.6x	---
United StatesSLNO Soleno Therapeutics Inc	2.3B	-15.8x	---
United StatesCGON CG Oncology Inc	2.4B	-27.8x	---
United StatesGERN Geron Corp	2.2B	-11.5x	---
United StatesNAMS NewAmsterdam Pharma Company NV	2.3B	-11.1x	---
United StatesKROS Keros Therapeutics Inc	2.4B	-10.7x	---
As of 2024-11-15

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.

Contact Information

Headquarters: 4275 Executive Square, Suite 950LA JOLLA, CA, United States 92037
Phone: 619-592-9775
Fax: 302-636-5454

Executives

Independent Chairman of the Board: Paul Sekhri
President, Chief Executive Officer, Director: Kevin Lind
Chief Financial Officer, Executive Vice President: Brandi Roberts
Executive Vice President, Chief Medical Officer: Randall Kaye
Independent Director: Vincent Aurentz

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.3B
Revenue (TTM)	$0.00
Shares Outstanding	39.0M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.04
EPS	$-2.24
Book Value	$1.67
P/E Ratio	-26.6x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Longboard Pharmaceuticals Inc
NASDAQ:LBPHUnited States

Search Criteria

Charts

Recent News

Nov 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by Dow Jones

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs), from 8:30AM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 7, 2024

Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 1, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of Shareholders, from 12:06PM ET on Friday Nov 01, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar